Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non–Small Cell Lung Cancer
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Purpose: One of the hallmarks of cancer cells is the excessive conversion of glucose to lactate under normoxic conditions, also known as the Warburg effect. Here, we tested whether the targeted inhibition of EGFR may revert this effect and reactivate mitochondrial oxidative phosphorylation in non–small cell lung cancer (NSCLC). Experimental Design: Sensitive (HCC827) and resistant (H1975 and H1993) NSCLC cells were treated with a panel of EGFR or MET inhibitors, and then tested for changes of EGFR signaling, glycolytic cascade, and mitochondrial function. Silencing of key glycolytic enzymes was then performed with targeted siRNAs. Furthermore, tumor-bearing nude mice treated with EGFR inhibitors were evaluated with 18F-FDG PET/CT and tumors were analyzed for glycolytic and mitochondrial proteins. Results: Effective inhibition of EGFR signaling in NSCLC cells induced a dramatic reduction of hexokinase II (HKII) and phospho-pyruvate kinase M2 (p-PKM2, Tyr105) levels as well as an upregulation of mitochondrial complexes subunits (OXPHOS). Accordingly, a decreased lactate secretion and increased intracellular ATP levels were also observed in response to EGFR inhibitors. Downregulation of HKII and PKM2 by targeted siRNA transfection did not cause upregulation of OXPHOS but enhanced the effects of EGFR TKIs. Conversely, selective inhibition of AKT and ERK1/2 caused OXPHOS upregulation and glycolysis inhibition, respectively. Similar findings were obtained in tumors from animals treated with appropriate EGFR inhibitors. Conclusions: Our findings indicate that EGFR inhibitors may reactivate oxidative phosphorylation of cancer cells and provide a mechanistic clue for the rational combination of agents targeting EGFR-dependent proliferation and glucose metabolism in cancer therapy. Clin Cancer Res; 21(22); 5110–20. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744 · cited 2×
“In particular, aberrant signaling from EGFR through the PI3K–AKT or RAS–MAPK pathways was reported to modulate the expression of a pool of genes encoding glucose transporters and most glycolytic enzymes (1, 9).”
BackgroundMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 2×
“However, despite initial response to treatment, virtually all NSCLC patients develop resistance to EGFR TKIs due to the occurrence of T790M secondary mutations in EGFR (15, 16) or to the amplification of MET receptor tyrosine kinase (17) and several compounds have been developed and tested to overcome EGFR TKIs resist…”
BackgroundMetabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233 · cited 2×
“Somatic mutations causing activation of oncogenes or loss of function of tumor-suppressor genes aremajor determinants of the glycolytic phenotype in cancer cells (8).”
BackgroundEpidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170 · cited 1×
“HCC827 cells are highly responsive to erlotinib due to the presence of an activating deletion of exon 19 (delE746_A750) of EGFR (21).”
BackgroundThe M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820 · cited 2×
“High levels of PKM2 are expressed in a variety of human tumors, including lung, breast, and colon cancer (28), and are reported to promote the Warburg effect in cancer cells (5, 6).”
BackgroundCancer cell metabolism: warburg and beyond
Hsu, P. P., & Sabatini, D. M. (2008) · Cell · doi:10.1016/j.cell.2008.08.021 · Cited by 2,452 · cited 1×
“Furthermore, the reduction of lactate secretion may increase extracellular pH, thus improving microenvironmental conditions of cancer cells and response to therapy (40).”
BackgroundThe Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes
Levine, A. J., & Puzio-Kuter, A. M. (2010) · Science · doi:10.1126/science.1193494 · Cited by 1,243 · cited 1×
“Many oncogenic signaling pathways were reported to cause the shift from oxidative phosphorylation to aerobic glycolysis in cancer cells (7, 8).”
BackgroundRational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083 · cited 1×
“EGFR is recognized as an oncogene driver in non–small cell lung cancer (NSCLC) because activating mutations in the kinase domain of EGFR cause an enhanced EGFR tyrosine kinase activity and a persistent activation of downstream signaling pathways that, in turn, drive oncogenesis and tumor progression (10).”
Background
Cited by
Oxidative Phosphorylation as an Emerging Target in Cancer Therapy
Ashton, T. M., McKenna, W. G., Kunz-Schughart, L. A., & Higgins, G. S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3070 · Cited by 1,135
Cuproptosis: mechanisms and links with cancers
Xie, J., Yang, Y., Gao, Y., & He, J. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01732-y · Cited by 801
Pyruvate Kinase M2 and Cancer: The Role of PKM2 in Promoting Tumorigenesis
Zahra, K., Dey, T., Ashish, Mishra, S. P., & Pandey, U. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00159 · Cited by 501
Lactate and lactylation in cancer
Chen, J., Huang, Z., Chen, Y., Tian, H., Chai, P., Shen, Y., Yao, Y., Xu, S., Ge, S., & Jia, R. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02082-x · Cited by 477
m6A-dependent glycolysis enhances colorectal cancer progression
Shen, C., Xuan, B., Yan, T., Ma, Y., Xu, P., Tian, X., Zhang, X., Cao, Y., Ma, D., Zhu, X., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01190-w · Cited by 437
Metadata
- Authors
- De Rosa, V., Iommelli, F., Monti, M., Fonti, R., Votta, G., Stoppelli, M. P., & Del Vecchio, S.
- Venue
- Clinical Cancer Research
- Published
- 2015-11-12
- Volume
- 21
- Issue
- 22
- Pages
- 5110-5120
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2136238497
- Cited by
- 150
- References
- 17
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non–Small Cell Lung Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-0375
- The paper
- De Rosa, V., Iommelli, F., Monti, M., Fonti, R., Votta, G., Stoppelli, M. P., & Del Vecchio, S. (2015). Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non–Small Cell Lung Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-0375
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.